Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2021 Oct 1

PMID 34594134

Citations 3

Authors

Desiree Kunadt

Friedrich Stolzel

Affiliations

Soon will be listed here.

Abstract

The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has increased constantly over the last years due to advances in transplant technology development, supportive care, transplant safety, and donor availability. Currently, acute myeloid leukemia (AML) is the most frequent indication for alloHCT. However, disease relapse remains the main cause of therapy failure. Therefore, concepts of maintaining and, if necessary, reinforcing a strong graft-versus-leukemia (GvL) effect is crucial for the prognosis and long-term survival of the patients. Over the last decades, it has become evident that effective immunosurveillance after alloHCT is an entangled complex of donor-specific characteristics, leukemia-associated geno- and phenotypes, and acquired resistance mechanisms. Furthermore, adoption of effector cells such as natural killer (NK) cells, alloreactive and regulatory T-cells with their accompanying receptor repertoire, and cell-cell interactions driven by messenger molecules within the stem cell and the bone marrow niche have important impact. In this review of pre- and posttransplant elements and mechanisms of immunosurveillance, we highlight the most important mechanisms after alloHCT.

Citing Articles

Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.

Pang Y, Holtzman N Best Pract Res Clin Haematol. 2023; 36(2):101475.

PMID: 37353287 PMC: 10291443. DOI: 10.1016/j.beha.2023.101475.

Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis.

Stadler M, Venturini L, Bunting I, Dammann E, Weissinger E, Schwarzer A Front Oncol. 2022; 12:867356.

PMID: 36059667 PMC: 9428843. DOI: 10.3389/fonc.2022.867356.

Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment.

Fowler D, Nattress C, Navarrete A, Barisa M, Fisher J Cancers (Basel). 2021; 13(23).

PMID: 34885108 PMC: 8657158. DOI: 10.3390/cancers13236000.

References

Zeiser R, Blazar B . Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179. PMC: 6034180. DOI: 10.1056/NEJMra1609337. View

Paczulla A, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H . Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019; 572(7768):254-259. PMC: 6934414. DOI: 10.1038/s41586-019-1410-1. View

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M . Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2018; 184(5):782-787. DOI: 10.1111/bjh.15691. View

Ghosh A, Barba P, Perales M . Checkpoint inhibitors in AML: are we there yet?. Br J Haematol. 2019; 188(1):159-167. PMC: 9549702. DOI: 10.1111/bjh.16358. View

Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

Rezvani A, Storer B, Guthrie K, Schoch H, Maloney D, Sandmaier B . Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 21(1):105-12. PMC: 4286386. DOI: 10.1016/j.bbmt.2014.09.021. View

Muffly L, Sheehan K, Armstrong R, Jensen K, Tate K, Rezvani A . Infusion of donor-derived CD8 memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv. 2018; 2(6):681-690. PMC: 5873230. DOI: 10.1182/bloodadvances.2017012104. View

Kollman C, Spellman S, Zhang M, Hassebroek A, Anasetti C, Antin J . The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2015; 127(2):260-7. PMC: 4713163. DOI: 10.1182/blood-2015-08-663823. View

Fleischhauer K, Shaw B . HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. Blood. 2017; 130(9):1089-1096. DOI: 10.1182/blood-2017-03-742346. View

10.

Duarte R, Labopin M, Bader P, Basak G, Bonini C, Chabannon C . Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019; 54(10):1525-1552. DOI: 10.1038/s41409-019-0516-2. View

11.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

12.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars F, Al Hinai A, Zeilemaker A . Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018; 378(13):1189-1199. DOI: 10.1056/NEJMoa1716863. View

13.

Ustun C, Courville E, DeFor T, Dolan M, Randall N, Yohe S . Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2015; 22(4):669-675. PMC: 4805453. DOI: 10.1016/j.bbmt.2015.10.024. View

14.

Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y . Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J. 2017; 7(12):634. PMC: 5802525. DOI: 10.1038/s41408-017-0007-x. View

15.

Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005; 23(24):5675-87. DOI: 10.1200/JCO.2005.07.061. View

16.

Laport G, Sheehan K, Baker J, Armstrong R, Wong R, Lowsky R . Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17(11):1679-87. PMC: 3175285. DOI: 10.1016/j.bbmt.2011.05.012. View

17.

Clift R, Buckner C, Appelbaum F, Bearman S, Petersen F, Fisher L . Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990; 76(9):1867-71. View

18.

Warren E, Deeg H . Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens. 2013; 81(4):183-93. PMC: 3645301. DOI: 10.1111/tan.12090. View

19.

Beavis P, Stagg J, Darcy P, Smyth M . CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012; 33(5):231-7. DOI: 10.1016/j.it.2012.02.009. View

20.

Robinson J, Halliwell J, Hayhurst J, Flicek P, Parham P, Marsh S . The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 2014; 43(Database issue):D423-31. PMC: 4383959. DOI: 10.1093/nar/gku1161. View